|Background and Objectives||Time Frame|
|A global bio-pharmaceutical company wanted to make informed clinical and commercial decisions to optimize commercial value for its asset (Product X) in development for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) in the US, EU5, and Japan. The objective was to:
|Approach and Recommendations (Methodology)||Results|
|SmartAnalyst adopted a two-phased approach to accomplish the objectives wherein the client’s foundational data was triangulated with information obtained from secondary research and in-depth, qualitative interviews with physicians, payors and patients; followed by quantitative market research.
Phase I: Disease and Market Landscape and Analog Analysis
Phase II: Quantitative Survey and Conjoint Design